Electrode cuff developed at WVU improves testing of medical treatments that use electricity to heal | WVU Today

Electrode cuff developed at WVU improves testing of medical treatments that use electricity to heal | WVU Today

The MouseFlex electrode made by WVU researchers will advance tests of vagus nerve stimulation, a chopping-edge bioelectronic treatment for circumstances that assortment from epilepsy to arthritis to hypertension. Listed here Justin Vankirk, a doctoral prospect in mechanical and aerospace engineering, releases microfabricated MouseFlex electrodes from a silicon wafer and solder-integrates potential customers to the system for electrochemical testing.
(WVU Photo/Paige Nesbit)

West Virginia University engineers are using a key step into
“bioelectronic medication,” a chopping-edge approach that uses electric existing as
a treatment for ache and sickness, with the improvement of MouseFlex. The unit
will aid investigation into a technique referred to as “vagus nerve stimulation” or
VNS.

The vagus nerve is dependable for involuntary body capabilities this kind of as heart
amount, respiration and digestion.

Mainly because VNS trials on mice will have to come about before new
bioelectronic treatment plans can be tested on humans, the MouseFlex — a small
electrode that has been shaped into a cuff condition, like the cuff of a shirt
sleeve — matches all over the vagus nerve of a mouse and provides electrical
impulses.

According to its developers, the MouseFlex outperforms present technologies when
it comes to withstanding both of those the electric powered recent flowing by way of it and the
managing it sustains during the course of surgery.

Biomedical engineer Tao Sunshine,
a investigate assistant professor at the Benjamin
M. Statler University of Engineering and Mineral Methods
, claimed the MouseFlex
not only allows far more successful rodent trials of VNS treatment options, but its design and style
could be tailored for people.

“This investigation is vital due to the fact our flexible electrodes
continue being functional soon after electrical stimulation,” Sunshine stated. “They attain
personal get hold of with the mouse vagus nerve and they tolerate surgical
managing. The MouseFlex will straight away gain neuroscientists and
scientists in neural engineering, but sufferers with drug-resistant illness are
the extensive-length beneficiaries.”

The review success surface in the journal Acta
Biomaterialia
.

 “Vagus nerve
stimulation is made use of for clients with situations these kinds of as drug-resistant
epilepsy,” stated Loren
Rieth
, associate professor in the Department
of Mechanical and Aerospace Engineering
. “VNS equipment handle individuals
ailments by stimulating the remaining vagus nerve in the neck, modifying nerve
signals that coordinate the function of the body’s organ devices. The vagus
nerve back links your brain to organs these kinds of as the coronary heart, lungs or belly. The name
‘vagus’ refers to ‘the wanderer,’ as the nerve branches and spreads to connect
all those organs with your mind.”

Rieth stated human vagus nerve branches in the neck “are about
a 10th of an inch in diameter and have around 100,000 nerve fibers. Cooked
spaghetti is a fantastic analogy for the size and ‘softness’ of the vagus nerve in
people, but our study deals with the vagus nerve in mice, which is 20 moments
smaller: the diameter of a thick strand of hair. The MouseFlex electrodes that
in shape all-around that nerve are about 10 instances thinner than a human hair.”

Due to the smaller sizing of the two the mouse vagus nerve and the
electrodes, it has been tough to interface with the nerve and difficult
for the electrodes to stay secure all over the system of electrical
stimulation.

Solar explained he was shocked by how nicely the MouseFlex fulfilled
those people worries.

“Robustness of electrodes on this degree is rare and pretty
thrilling,” he reported. “All MouseFlex electrodes remained functional immediately after one particular
billion cycles of electrical stimulation at 8 milliamps — the most
intense electrical stimulation I’ve witnessed to day in peer investigation.

“After we carried out the surgical procedures, then eliminated the electrodes
and cleaned them, the electrochemical effectiveness mainly reversed to the degree
it had before the surgery, which usually means that these electrodes do tolerate
surgical handling. That’s pretty essential for clinical research and for
commercialization.”

Rieth estimated that around 125,000 men and women all-around the world
have VNS stimulators for epilepsy or depression. Nevertheless, a new affliction currently being
evaluated for VNS treatment method is rheumatoid arthritis, an autoimmune ailment in
which the immune technique assaults the body’s joints. 1 enterprise — SetPoint
Health care — is conducting a multicenter medical trial on VNS to handle rheumatoid
arthritis, and Dr. Peter
Konrad
, chair of the WVU University of
Drugs
Division of
Neurosurgery
inside the Rockefeller
Neuroscience Institute
, is leading a person of the scientific trial websites at Health and fitness Sciences.

“If procedure for autoimmune ailments like rheumatoid
arthritis is effective and units are accepted for that purpose, then the quantity of
VNS clients will very likely enhance appreciably,” Rieth predicted, pointing to
other widespread health care ailments with the likely to reply to
bioelectronic procedure, which include reactive airway disorder and heart sickness.

“VNS systems don’t have key protection issues,” he reported.
“The surgical procedure to place the electrode and stimulator does have hazards, but
neurosurgeons observe nicely-proven methods. There can be aspect outcomes
these types of as voice alterations from stimulation, which for epilepsy comes about just about every handful of
minutes, but these hardly ever call for turning off the stimulator. Of study course, new
remedies could possibly have distinctive protection issues, and that is a critical part of
the Foodstuff and Drug Administration’s review system.”

Sunlight observed numerous added ailments for which vagus
nerve stimulation utilizing adaptable electrodes like the MouseFlex shows promise:
depression, being overweight and large blood force, also regarded as hypertension.

“For a lot of drug-resistant sufferers, responsible and protected vagus
nerve modulation opens new avenues to helpful remedies with several or no aspect
consequences,” Sun said. “And our MouseFlex technology could also interface with
nerves apart from the vagus nerve — the sciatic and sacral nerves and the spinal
cord, for instance. Stimulating the spinal cord is productive for managing
persistent suffering and could restore misplaced movement capacity for paralyzed sufferers.”

Editor’s take note: The protocols for the in-vivo study
regarding stimulation basic safety and efficacy of MouseFlex electrodes were accredited
by the Institutional Animal Care and Use Committee (IACUC) at the Feinstein
Institutes for Medical Investigation (Manhasset, NY, United states). The Feinstein Institutes
comply with the National Institute of Health and fitness (NIH) pointers for the moral
cure of animals.

-WVU-

mm/04/03/23

MEDIA Make contact with: Micaela Morrissette
Study Writer
WVU Research Communications

304-709-6667
micaela.morrissette@mail.wvu.edu

OR

Paige Nesbit
Advertising and Communications Director
WVU Statler Faculty of Engineering and Mineral Resources

304-293-4135
paige.nesbit@mail.wvu.edu

Contact 1-855-WVU-News for the newest West Virginia University
news and information from WVUToday.

Abide by @WVUToday
on Twitter.

Port Medical Management Introduces App for Remote COVID-19 Testing

Port Medical Management Introduces App for Remote COVID-19 Testing

Port Medical Management Introduces App for Remote COVID-19 Testing

Posted
Mar 19, 2023 7:34 PM by

Port Clinical Administration

Port Medical Administration has done beta-testing on a new cellular app designed to make it possible for maritime crewmen to administer their own COVID-19 assessments, from any spot, and get quick tracked success pursuing confirmation by a Port Health-related Administration group member.  The Port Clinical Administration SeaScan application, formulated by cell app specialists DOM&TOM (www.DomandTom.com), was commissioned by Port Health care founder and CEO Dean Crassas, influenced by his conversations with ship owners, agents, and P&I Golf equipment.

&#13
&#13

“Our sector is generally intrigued in ‘better, a lot quicker, and a lot less costly,’” notes Crassas, “and Port Health care Management’s SeaScan app delivers on all counts.”

&#13
&#13

In 2020, with the onset of the COVID-19 pandemic, the transport sector confronted an unprecedented obstacle as most nations around the world and airways commenced implementing required COVID-19 testing for all tourists. Ship house owners and agents promptly learned the logistical troubles of testing on-signing and off-signing crewmembers, and the will need for expediting check benefits to permit for well timed crew modifications. 

&#13
&#13

Screenshot from the SeaScan app’s interface

&#13
&#13

&#13
&#13

With the initially wave of pandemic-connected cases, Port Clinical Management’s functions workforce took actions to be certain that the corporation was uniquely positioned to provide Quick PCR and Antigen tests in all US ports. In shorter buy, Port Clinical Administration became an field chief in addressing this problem for owners and brokers in the most efficient and value-productive fashion.

&#13
&#13

“We’re looking at a lot less stringent specifications for screening of late,” observes Crassas, “but the genuine possibility of traveling crew members boarding vessels though unknowingly contaminated with COVID-19 stays a authentic issue for ship owners. They nevertheless want and require this safety of testing, but there is developing resistance to the higher prices involved with laboratory testing.”

&#13
&#13

Port Medical’s pursuit of a way to benefit from the much considerably less costly, self-administered Antigen COVID-19 checks, in a method that would allow these results to be tracked and verified, prompted his overture to DOM&TOM, who have delivered electronic options service to many Fortune 500 businesses. The alternative they made is Port Medical’s new SeaScan app. This cellular application will allow crew users to take a look at on their own and consists of a 3-move verification procedure, with photograph affirmation and third-get together corroboration of effects by Port Clinical Management.  This substantially reduces the expense for ship owners, and nonetheless gives an productive implies of guarding the crew associates and other individuals from spreading COVID-19 on vessels.

&#13
&#13

For a lot more info on employing this new, cost and time conserving technological innovation, stop by Port Clinical Management at www.portmedical.internet or call at 713-526-PORT (7678).

&#13

The thoughts expressed herein are the author’s and not essentially individuals of The Maritime Government.

United States Women Health Laboratory Testing Markets Report 2022-2030 Featuring Ascension, EKF, Gateway Genomics, Laboratory Corp of America, Myriad Genetics, Natera, Ovia Health, Roche, & Yourgene

United States Women Health Laboratory Testing Markets Report 2022-2030 Featuring Ascension, EKF, Gateway Genomics, Laboratory Corp of America, Myriad Genetics, Natera, Ovia Health, Roche, & Yourgene

DUBLIN, Feb. 20, 2023 /PRNewswire/ — The “U.S. Women Health Laboratory Testing Market – A Region-Wise Analysis: Focus on U.S. Women Health Laboratory Testing Market – Analysis and Forecast, 2022-2030” report has been added to  ResearchAndMarkets.com’s offering. 

 

The U.S. women health laboratory testing market was valued at $72.8 billion in 2021 and is anticipated to reach $106.8 billion by 2030, witnessing a CAGR of 4.30{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} during the forecast period 2022-2030.

The market is driven by factors such as the increase in the prevalence of infectious diseases and cancer in women, rising awareness regarding women health-related tests, the rising average maternal age leading to increased risk of fetal chromosomal aneuploidies, and the upsurge in reproductive health problems leading to increased demand for laboratory testing in women.

The U.S. women health laboratory testing market is in the developed phase. The advancements in diagnostic technologies including applications of genetic testing in women’s health and the significant number of mergers and acquisitions of companies to attain a better market share are some of the major opportunities in the U.S. women health laboratory testing market.

How can this report add value to an organization?

The different segment of the report helps the reader understand the different type of laboratory tests/services for women’s health available in the market.

Moreover, the study provides the reader with a detailed understanding of tests/services that fall under the different segments, which are hereditary cancer, carrier screening, prenatal screening, and diagnostic testing, reproductive health and infectious diseases, and obstetrics and gynecology.

Growth/Marketing Strategy: The U.S. women health laboratory testing market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, merger and acquisitions, funding activities, and regulatory and legal approvals.

The favored strategy for the companies has been regulatory and legal activities to strengthen the position of their product in the U.S. market. For instance, in October 2019, Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic for Treatment with Zejula in Late-line Ovarian Cancer.

Recent Developments in the U.S. Women Health Laboratory Testing Market

  • In November 2022, Roche Holdings launched its Cobas 5800, a new molecular diagnostic system to expand access to PCR testing in the U.S. The system can assist in the diagnosis of Infectious diseases, such as HIV, Hepatitis, transplant-associated viral illnesses, and respiratory and STIs.

  • In February 2022, the Laboratory Corporation of America Holdings established a strategic partnership with Ascension to expand its testing capabilities.

  • In January 2022, Yourgene announced that it has signed a strategic partnership agreement with EKF Diagnostics Holdings plc a point-of-care business with accredited laboratory testing capabilities in the U.S.

  • In November 2022, Myriad Genetics announced that it has acquired Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests.

  • In August 2022, Natera, Inc. announced that the company has proactively filed a pre-submission to the FDA for its Panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process.

Market Segmentation

  • The U.S. women health laboratory testing market (hereditary cancer) is expected to be dominated by the cervical cancer segment.

  • The U.S. women health laboratory testing market (prenatal screening and diagnostic testing) is dominated by the non-invasive prenatal testing segment.

  • The U.S. women health laboratory testing market (reproductive health and infectious diseases) is dominated by the HIV testing segment.

  • The U.S. women health laboratory testing market (by region) is dominated by the South region segment.

Companies Featured

Key Topics Covered:

1 Markets

1.1 U.S. Market Outlook

1.1.1 Product Definition

1.1.2 Inclusion and Exclusion Criteria

1.2 Business Dynamics

1.2.1 Impact Analysis

1.2.2 Business Drivers

1.2.2.1 Increase in the Prevalence of Infectious Diseases and Cancer in Women Leading to Increased Demand for Laboratory Diagnostics

1.2.2.2 Rising Awareness Regarding Women Health-Related Tests

1.2.2.3 Rising Average Maternal Age Leading to Increasing Risk of Fetal Chromosomal Aneuploidies

1.2.2.4 Upsurge in Reproductive Health Problems Leading to Increased Demand for Laboratory Testing in Women

1.2.3 Business Restraints

1.2.3.1 Stringent Regulatory Guidelines Related to Laboratory Testing Hindering the Market Growth in the U.S.

1.2.3.2 Disparity in Awareness of Pregnancy and Fertility Issues in the Different Regions of the U.S.

1.2.4 Business Opportunities

1.2.4.1 Advancement in Diagnostic Technologies, including Applications of Genetic Testing in Women’s Health

1.2.4.2 Healthcare Disparities in the Rural Counties of the U.S.

1.2.4.3 Gap in Healthcare for Women of Reproductive Age with Psychological Distress

1.2.4.4 Significant Number of Mergers and Acquisitions by Companies to Attain a Better Market Share

2 U.S. Women Health Laboratory Testing Market (by Hereditary Cancer)

2.1 Overview

2.2 Breast Cancer

2.2.1 Epidemiology

2.2.2 Testing Market

2.2.3 Testing Market (by Region)

2.3 Cervical Cancer

2.4 Ovarian Cancer

3 U.S. Women Health Laboratory Testing Market (by Carrier Screening)

3.1 Overview

3.1.1 Testing Market

3.1.2 Testing Market (by Region)

4 U.S. Women Health Laboratory Testing Market (by Prenatal Screening and Diagnostic Testing)

4.1 Overview

4.2 Non-Invasive Prenatal Testing (NIPT)

4.3 Maternal Serum Screening (MSS)

4.4 Prenatal Diagnostic Testing

5 U.S. Women Health Laboratory Testing Market (by Reproductive Health and Infectious Diseases)

5.1 Overview

5.2 Pregnancy and Ovulation Testing

5.3 HPV Testing

5.4 PAP Smear Testing

5.5 HIV Testing

5.6 CT/NG Testing

5.7 Preimplantation Genetic Testing (PGT)

5.8 Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia)

5.9 Herpes Simplex Virus (HSV)

5.10 Hepatitis

5.11 Vaginal Infections

6 U.S. Women Health Laboratory Testing Market (by Obstetrics and Gynaecology)

6.1 Overview

6.1.1 Testing Market (by Region)

For more information about this report visit https://www.researchandmarkets.com/r/eetogi-s-women-health?w=5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

Cision

View original content:https://www.prnewswire.com/news-releases/united-states-women-health-laboratory-testing-markets-report-2022-2030-featuring-ascension-ekf-gateway-genomics-laboratory-corp-of-america-myriad-genetics-natera-ovia-health-roche–yourgene-301750614.html

SOURCE Research and Markets